Pilut Ciprian Nicolae, Citu Cosmin, Gorun Florin, Bratosin Felix, Gorun Oana Maria, Burlea Bogdan, Citu Ioana Mihaela, Grigoras Mirela Loredana, Manolescu Diana, Gluhovschi Adrian
Department of Microbiology, Faculty of Medicine, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Department of Obstetrics and Gynecology, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Diagnostics (Basel). 2022 Mar 27;12(4):824. doi: 10.3390/diagnostics12040824.
COVID-19 has been associated with cardiovascular consequences, including myocardial infarction, thromboembolic events, arrhythmia, and heart failure. Numerous overlapping mechanisms, such as the IL-6 dependent cytokine storm and unopposed angiotensin II stimulation, could be responsible for these consequences. Cardiac damage is hypothesized to be a consequence of the direct viral infection of cardiomyocytes, resulting in increased metabolic demand, immunological activation, and microvascular dysfunction. Patients with pre-existing chronic heart failure are therefore at increased risk of decompensation, further heart damage, and significant health deterioration. Based on the aforementioned assumptions, we developed a study aiming to provide a detailed description of changes in biological parameters and cardiac injury markers of patients with heart failure and SARS-CoV-2 infection by correlating them with the clinical presentation and COVID-19 vaccination status, to predict the probability of ICU admission based on their initial hospital presentation. A two-year retrospective study was performed on heart failure patients with a history of SARS-CoV-2 infection and detailed records of biological biomarkers; a total of 124 eligible patients with COVID-19 and 236 without COVID-19 were recruited. Patients with heart failure and SARS-CoV-2 infection had significantly elevated baseline biological parameters and cardiac markers compared to those without COVID-19. Several cardiac injury markers were identified as significant independent risk factors for ICU admission: CK-MB (HR = 4.1, CI [2.2-6.9]), myoglobin (HR = 5.0, CI [2.3-7.8]), troponin-I (HR = 7.1 [4.4-9.6]), troponin-T (HR = 4.9, CI [1.7-7.4]). The elevation of a basic panel of acute inflammation markers (CRP, IL-6, fibrinogen), D-dimers, and BNP was also a significant risk factor. The follow-up of survivors at four weeks after viral clearance determined a worsened clinical picture by NYHA classification, worsened cardiac ultrasound findings, and a mild improvement in cardiac and inflammatory markers. Increased levels of myocardial damage parameters in association with cardiac ultrasound findings and basic inflammatory markers may enable early risk assessment and triage in hospitalized heart failure patients infected with SARS-CoV-2.
新冠病毒病(COVID-19)与心血管方面的后果相关,包括心肌梗死、血栓栓塞事件、心律失常和心力衰竭。许多重叠的机制,如白细胞介素-6依赖性细胞因子风暴和无对抗的血管紧张素II刺激,可能是这些后果的原因。心脏损伤被推测是心肌细胞直接病毒感染的结果,导致代谢需求增加、免疫激活和微血管功能障碍。因此,患有慢性心力衰竭的患者失代偿、进一步心脏损伤和健康状况显著恶化的风险增加。基于上述假设,我们开展了一项研究,旨在通过将心力衰竭合并SARS-CoV-2感染患者的生物学参数和心脏损伤标志物的变化与临床表现及COVID-19疫苗接种状况相关联,详细描述这些变化,从而根据患者最初的医院表现预测入住重症监护病房(ICU)的概率。对有SARS-CoV-2感染病史且有生物学生物标志物详细记录的心力衰竭患者进行了一项为期两年的回顾性研究;共招募了124例符合条件的COVID-19患者和236例未感染COVID-19的患者。与未感染COVID-19的患者相比,心力衰竭合并SARS-CoV-2感染的患者基线生物学参数和心脏标志物显著升高。几种心脏损伤标志物被确定为入住ICU的显著独立危险因素:肌酸激酶同工酶(CK-MB)(风险比[HR]=4.1,可信区间[CI][2.2 - 6.9])、肌红蛋白(HR = 5.0,CI [2.3 - 7.8])、肌钙蛋白I(HR = 7.1 [4.4 - 9.6])、肌钙蛋白T(HR = 4.9,CI [1.7 - 7.4])。一组基本的急性炎症标志物(C反应蛋白、白细胞介素-6、纤维蛋白原)、D-二聚体和脑钠肽(BNP)的升高也是一个显著的危险因素。对病毒清除后四周的幸存者进行随访发现,根据纽约心脏协会(NYHA)分级,临床情况恶化,心脏超声检查结果恶化,心脏和炎症标志物有轻度改善。心肌损伤参数水平升高与心脏超声检查结果及基本炎症标志物相关,这可能有助于对感染SARS-CoV-2的住院心力衰竭患者进行早期风险评估和分诊。